Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711756 | 0.92 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10305680 | 0.89 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1359901 | 0.83 | — | — | |
| SCHEMBL9257399 | 0.80 | — | — | |
| SCHEMBL710902 | 0.77 | — | — | |
| SCHEMBL1359715 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11372360 | 0.76 | CA2 (0.32) | — | |
| SCHEMBL12137507 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL15303985 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL10305673 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016046-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-11 | — | — | EP | disclosed |
| EP-2016046-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-11 | — | — | EP | disclosed |
| US-8066974-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-8066974-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-8066974-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-20090136425-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-05-28 | — | — | US | disclosed |
| US-20090136425-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-05-28 | — | — | US | disclosed |
| US-20090136425-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-05-28 | — | — | US | disclosed |
| EP-2016046-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007133088-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136425-A1 | CONTRAST AGENTS | IPO8, IPO4, IPO11 | ALDH1A1 2182/4885HPGD 2564/4885SMN1; SMN2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.